Dr Roberta Mazzieri

Senior Research Fellow

The University of Queensland Diamantina Institute
Faculty of Medicine
r.mazzieri@uq.edu.au
+61 7 344 37089

Overview

Dr Roberta Mazzieri obtained her PhD in Genetic Science from the University of Pavia (Italy) and subsequently undertook one post-doctoral position at the New York University (USA) and two at the San Raffaele Scientific Institute in Milan (Italy). Since her PhD studies, she focused on understanding the tumor microenvironment by examining a number of related molecular pathways including the uPA/uPAR system and TGFß1 activation. During her last postdoc with Prof. Naldini, she made her most significant and clinically-applicable contribution to cancer research by exploiting advanced gene transfer technologies to study the interplay between tumour associated macrophages and tumor angiogenesis. She demonstrated that targeting the ANG2/TIE2 pathway inhibits tumor angiogenesis, growth, and metastasis by disabling the pro-angiogenic activity of tumour associated Tie2-expressing macrophages (TEMs), thus impeding the emergence of evasive resistance to anti-angiogenic therapy. In 2011 this work was featured as cover article in Cancer Cell. Moreover, by turning TEMs into efficient delivery vehicles, she worked to target a key immune modulatory protein, IFN-alpha, to tumors and achieved substantial antitumor activity in several tumor models including a human model of breast cancer. This work was published as cover article in Science Translational Medicine.

In 2012 she was nominated by the Young Ambassadors from the Metastasis Research Society (MRS) to speak at MRS meeting in recognition of her potential to launch independent research and contribute to high-quality publications. The same year she was recruited by the University of Queensland (Brisbane, Australia) to establish her own research group. At the UQ-Diamantina Institute she is now continuing her work on targeting pro-tumoural macrophages to inhibit tumour progression with a specific focus on breast cancer metastasis. She is also continuing her work on demonstrating the therapeutic potential of turning tumour infiltrating macrophages into efficient delivery vehicles of anti-tumoural biomolecules.

Research Interests

  • Tumour associated Tie2+ macrophages: novel targets and effectors of anti-breast cancer therapies
    While advances in treatment and screening have greatly improved outcomes for most breast cancer patients, major unmet needs remain for treatment of patients with metastatic disease. Breast cancer has not benefitted to the same extent as other cancers from the recent introduction of immunotherapies due to poor inherent immunogenicity of breast tumours associated with a highly immunosuppressive microenvironment. New strategies are needed to overcome these limitations. We identified and characterized a subpopulation of pro-tumoural macrophages: the Tie2-expressing monocytes/macrophages (TEMs) endowed with pro-angiogenic and immunosuppressive activities, both involving signalling through the ANG2/TIE2 pathway. Indeed we demonstrated that blocking the ANG2/TIE2 pathway disables the pro-angiogenic activity of TEMs resulting in inhibition of tumour angiogenesis, growth, and metastasis in mouse models of breast carcinogenesis. We are now investigating whether the in vivo blockade of ANG2 is not only inhibiting the pro-angiogenic activity of TEMs, but also reverting their immunosuppressive activity, thus providing a strong rational for the development and testing of new combination therapies. Moreover, by exploiting the tumor homing ability of TEMs we turned them into an efficient vehicle for the tumor-targeted delivery of a potent immune-stimulatory molecule: interferon-alpha(IFNα) We think that the multiple activities of type I IFNs in the complex network of cell interactions that lead to activation and deployment of immune responses may represent a valid strategy to promote and improve the outcome of cancer immunotherapy for the treatment of advanced breast cancer including lung and bone metastasis. With the final goal of developing more effective anti-tumour therapies, we propose to investigate whether inhibition of the pro-tumoural activity of macrophages results in a less immunosuppressive microenvironment able to enhance the efficacy of promising cancer immunotherapies. The results of the proposed studies may impact on the future course of cancer therapy by providing proof-of-feasibility of new combination therapies. More recently we also started exploring the efficacy and feasibility of combining TEM-mediated delivery of IFNα with immunogenic chemotherapy or nanoparticles mediated vaccination.
  • Extending our research to Glioblastoma
    The most prevalent brain tumour, Glioblastoma multiforme (GBM) is associated with a dismal median overall survival of 1–2 years and a 5-year survival rate of <10 %. Temozolomide, surgical resection and radiation comprise the current standard of care for GBM, but even standard therapy has only modestly improved overall survival. New strategies are therefore highly needed. We previously demonstrated the anti-tumour efficacy of our TEM-mediated delivery of IFNα in a xenografted model of human GBM, and proved the ability of our genetically engineered monocytes to deliver IFNα to brain tumours. As a proof of concept, we are now testing this strategy in immunocompetent mouse models of GBM to demonstrate reversion of the immunosuppressive microenvironment in this type of tumour, thus providing a strong rationale for the design of new combination treatments with emerging immunotherapies, immunogenic chemotherapy and vaccination.

Qualifications

  • Doctor of Philosophy, Università degli Studi di Pavia

Publications

View all Publications

Supervision

  • Doctor Philosophy

  • Doctor Philosophy

  • Doctor Philosophy

View all Supervision

Publications

Journal Article

PhD and MPhil Supervision

Current Supervision

  • Doctor Philosophy — Principal Advisor

  • Doctor Philosophy — Associate Advisor

  • Doctor Philosophy — Associate Advisor